Status:
TERMINATED
Ulcerative Colitis - Vedolizumab- With/Without Prior Exposure to Anti-TNF（Tumor Necrosis Factor）Therapy
Lead Sponsor:
Stanford University
Collaborating Sponsors:
Takeda
University of Western Ontario, Canada
Conditions:
Ulcerative Colitis
Eligibility:
All Genders
18+ years
Brief Summary
A case-control study to evaluate the immunoinflammatory effect of prior exposure to anti-TNF therapy in patients with ulcerative colitis starting vedolizumab therapy
Detailed Description
Inflammatory bowel disease (IBD)- ulcerative colitis (UC) and Crohn's disease (CD)- are chronic conditions of the gastrointestinal tract. Treatment generally consists of immunosuppression to modify th...
Eligibility Criteria
Inclusion
- adult patients (\>18 years old)
- clinical diagnosis of inflammatory bowel disease (Ulcerative Colitis)
- clinical indication for biologic therapy
- naive or failed anti-TNF therapy previously
Exclusion
- patients allergic or intolerant to vedolizumab,
- past use of vedolizumab;
- patient unable to give consent to enter the study
Key Trial Info
Start Date :
October 29 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 11 2020
Estimated Enrollment :
1 Patients enrolled
Trial Details
Trial ID
NCT03802214
Start Date
October 29 2020
End Date
December 11 2020
Last Update
December 21 2020
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Stanford University
Stanford, California, United States, 94305
2
University of Western Ontario
London, Ontario, Canada, N6A5A5